Print This Page

European Bioinformatics Institute (EBI)                                                                        

The Office of Cancer Clinical Proteomics Research is working closely with the European Bioinformatics Institute to coordinate bioinformatics standards development for clinical proteomics. EBI is a non-profit academic organization associated with the European Molecular Biology Laboratory that manages databases of biological data, including nucleic acids, protein sequences, and macromolecular structures. It is the premier center for research and services in bioinformatics in the European Union (EU). Recently, the EBI invited the OCCPR to serve as an Associate Partner to Proteomics Data Collection (ProDaC), on a grant awarded from the EU to the EBI. The ProDaC program will develop international data standards with recommendations from the HUPO-PSI. The National Cancer Institute (NCI) is the only Federal research agency invited to participate in this program as an associate partner.

Food and Drug Administration (FDA)                                                                                   

The Food and Drug Administration (FDA) launched the Critical Path Research Initiative to identify, develop, and apply state-of-the-art genomics and proteomics technologies to medical product development to improve the accuracy of the tests used to predict the safety and efficacy of investigational medical products. In alignment with the Critical Path Initiative, a memorandum of understanding (MOU) between the FDA and the NCI became effective on April 5, 2007. The purpose of this MOU was to establish a formal collaboration regarding proteomics science and technology to accelerate proteomics technology development and application in clinical settings. FDA and NCI are collaborating in areas involving proteomics such as: Sample collection, preparation, storage and processing; bioinformatics and data analysis; discovery and validation of biomarkers; and surrogate biomarkers of cancer development and drug response, including standardization among technology platforms and assay standards development.

Human Protein Atlas

The Human Protein Atlas provides additional characterization using tissue microarrays for antibodies produced by the NCI through the Antibody Characterization Program. The Human Protein Atlas (HPA) is a well-recognized, mature resource for tissue microarray analysis expression data for thousands of antibodies across hundreds of normal human tissues and cancer cells. The data is publicly available and presented as high resolution images of immunohistochemically stained tissues and cell lines annotated with links to proteins for specific genes or by browsing individual chromosomes.

Korea Institute of Science and Technology (KIST)                                                              

NCI has entered into a memorandum of understanding with the Korea Institute of Science and Technology (KIST) to promote proteomic technology optimization and standards implementation in large-scale international programs.

National Heart, Lung, and Blood Institute

The Proteomics Center Program of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), is a trans-disciplinary program that supports proteomic technology development, molecular mechanistic and functional studies as well as application of proteomic approaches and technologies to clinical questions. OCCPR has a memorandum of understanding with this NHLBI program to help foster greater cooperation through the sharing of reagents and protocols, the verification of candidate protein markers, and to help facilitate the development of bioinformatics standards in proteomics.

National Institute of Standards and Technology (NIST)                         

NCI collaborates with NIST to develop mass spectrometry (MS)-based technology assessment reference materials and quality control bioinformatic tools to be used by the CPTAC teams and the broad research community. These reference materials, along with software tools and datasets developed by the NCI, are the first-of-their-kind resources that will be instrumental for the evaluation of existing MS-based technologies and for the comparison of current with emerging technologies of interest to the proteomic community.

The Cancer Genome Atlas (TCGA)

The Cancer Genome Atlas (TCGA) Project is a large-scale collaborative effort to characterize the genomic changes that occur in cancer. The project, co-funded by NCI and the National Human Genome Research Institute (NHGRI), currently involves more than two dozen participating institutions. TCGA and the Clinical Proteomic Tumor Analysis Consortium are working together to further elucidate the cancer phenotype through proteomic analysis of cancer tumors that have been genomically characterized by TCGA investigators.